Transcatheter Mitral & Tricuspid Therapies (TMTTs) are the future of Edwards – Estimated to be a more than $5 billion opportunity by 2028, Edwards will discuss its multiple transcatheter programs aime...
Edwards Lifesciences, Bavaria, Germany (Hybrid) Innovation starts from the heart. Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical car...
Transcatheter Mitral & Tricuspid Therapies (TMTTs) are the future of Edwards – Estimated to be a more than $5 billion opportunity by 2028, Edwards will discuss its multiple transcatheter programs aime...
Edwards Lifesciences, Bavaria, Germany (Hybrid) Innovation starts from the heart. Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical car...